Clinical trial
MDD POC Study GSK372475 Subjects Depressive Disease
NCT00420641 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00420641 |
|---|---|
| Title | MDD POC Study GSK372475 Subjects Depressive Disease |
| Official title | A Ten-week, Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled, Paralleled-Group, Flexible-Dose Study Evaluating the Efficacy, Safety and Tolerability of GSK372475 or Paroxetine Compared to Placebo in Adult Subjects Diagnosed With Major Depressive Disorder |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Depressive Disorder |
| Intervention type | Drug, Other |
| Interventions | GSK372475, Paroxetine, Placebo |
| Enrollment | 492 |
| Start date | Dec 19, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Oct 15, 2008 |
| First posted | Jan 11, 2007 |
| Last update posted | Feb 5, 2018 |
| Countries | Bulgaria, Canada, Chile, Costa Rica, Croatia, France, Germany, India, Italy, Poland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: